SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Eric Klein

6

McKesson

MCK

America’s largest pharmaceutical distributor slips one spot on the 500 this year, but the continued strength of its distribution business–serving as the middleman between manufacturers and pharmacies–lifted revenues 3% in 2017. The acquisition of Rexall Health powered some of that growth as did trends like the nation’s climbing drug prices and rising drug utilization rates. McKesson also moved ahead with its plan to divest its technology businesses in deals with Change Healthcare and Allscripts. The company, along with the country’s other large drug distributors, remains a target of litigation over its alleged role in the nation’s opioid epidemic.

Looking for leads, investment insights, or competitive intelligence?

CEO

John H. Hammergren

CEO Title

Chairman, President & Chief Executive Officer

Sector

Wholesalers

Industry

Wholesalers: Health Care

HQ Location

San Francisco

Years on Fortune 500 List

24

Employees

64,500

Figures are for fiscal year ended March 31, 2017.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$198,5333.1%
Profits ($M)$5,070.0124.5%
Assets ($M)$60,969
Total Stockholder Equity ($M)$11,095
Market Value — as of March 29, 2018 ($M)$29,067
Profit Ratios
Profit as % of Revenues2.6%
Profits as % of Assets8.3%
Profits as % of Stockholder Equity45.7%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)22.73
EPS % Change (from 2016)134.3%
EPS % Change (5 year annual rate)32.4%
EPS % Change (10 year annual rate)22.5%
Total Return
Total Return to Investors (2017)11.9%
Total Return to Investors (5 year, annualized)10.7%
Total Return to Investors (10 year, annualized)9.9%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about McKesson

6 More States Just Sued the Oxycontin Maker. How It Could Dramatically Alter the Price of an Opioid Settlement

The decision to sue is seen as an acknowledgment opioid makers won’t get serious about settling until the cases go to trial.

Read More →
Why Trump's Big Drug Price Speech Sent Health Care Stocks Soaring

The president's drug price proposals didn't shake big pharma and other health care companies.

Read More →
The Justice Department Is Getting In on the War on Opioids

Attorney General Jeff Sessions announced a "statement of intent" to prop up suits against opioid makers and distributors.

Read More →
Amazon, Berkshire Hathaway and J.P. Morgan Are Forming a Non-Profit Health Care Venture

Sparking a selloff in the shares of a host of health care-related companies.

Read More →